drugset / Trial / NCT03824171

Evaluating the Pharmacokinetic Characteristics of AD-102 in Healthy Volunteers

NCT03824171

Phase 1 Completed 52 enrolled Addpharma Inc.
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate the pharmacokinetic characteristics of AD-102 in healthy male subjects

Timeline

Start
2019-02-28
Primary completion
2019-03-27
Completion
2019-04-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Cholecalciferol Other / unclassified 800 iu Oral
Subject Raloxifene Other / unclassified 45 mg Oral
Subject Raloxifene Other / unclassified 60 mg Oral

Indications